UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
- --------------------------------------------------------------------------------
SCHEDULE 13G
(Amendment No. 2)
Under the Securities Exchange Act of 1934
Interferon Sciences, Inc.
-------------------------
(Name of Issuer)
Common Stock, no par value per share
------------------------------------
(Title of Class of Securities)
45890301
--------
(CUSIP Number)
- --------------------------------------------------------------------------------
Check the following box if a fee is being paid with this statement. |_|
Exhibit Index is at Page 6
Page 1 of 9
<PAGE>
CUSIP No. 4589031
(1) Names of Reporting Persons
S.S. or I.R.S. Identification Nos. of Above Persons
Citicorp; 13-2614988
----------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group
[ ] (a)
-------------------------------------------------------------------
[ ] (b)
-------------------------------------------------------------------
(3) SEC Use Only
-----------------------------------------------------------
- --------------------------------------------------------------------------------
(4) Citizenship or Place of Organization Delaware
---------------------------------
------------
Number of (5) Sole Voting Power -0-
Shares --------------------------
Beneficially (6) Shared Voting Power 1,710,834
Owned by ------------------------
Each (7) Sole Dispositive Power -0-
Reporting ---------------------
Person (8) Shared Dispositive Power 1,710,834
With -------------------
------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person*
1,710,834
-----------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
-------
(11) Percent of Class Represented by Amount in Row (9) 4.0%
--------------------
(12) Type of Reporting Person BK
---------------------------------------------
* The reporting person is a pledgee with limited voting and dispositive power
pursuant to certain voting trust agreements. The reporting person disclaims
beneficial ownership of these securities, and this report shall not be deemed an
admission that the reporting person is the beneficial owner of such securities
for purposes of Section 13 or for any other purpose.
Page 2 of 9
<PAGE>
CUSIP No. 4589031
(1) Names of Reporting Persons
S.S. or I.R.S. Identification Nos. of Above Persons
Citibank N.A.; 13-5266470
----------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group
[ ] (a)
----------------------------------------------------------------------
[ ] (b)
----------------------------------------------------------------------
(3) SEC Use Only
-----------------------------------------------------------
- --------------------------------------------------------------------------------
(4) Citizenship or Place of Organization New York
---------------------------------
-------------
Number of (5) Sole Voting Power -0-
Shares --------------------------
Beneficially (6) Shared Voting Power 1,710,834
Owned by -------------------------
Each (7) Sole Dispositive Power -0-
Reporting ---------------------
Person (8) Shared Dispositive Power 1,710,834
With --------------------
-------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person*
1,710,834
-----------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
-------
(11) Percent of Class Represented by Amount in Row (9) 4.0%
---------------------
(12) Type of Reporting Person BK
--------------------------------------------
* The reporting person is a pledgee with limited voting and dispositive power
pursuant to certain voting trust agreements. The reporting person disclaims
beneficial ownership of these securities, and this report shall not be deemed an
admission that the reporting person is the beneficial owner of such securities
for purposes of Section 13 or for any other purpose.
Page 3 of 9
<PAGE>
SCHEDULE 13G
Item 1(a) Name of Issuer:
Interferon Sciences, Inc.
------------------------------------------------------------
Item 1(b) Address of Issuer's Principal Executive Offices:
783 New Jersey Avenue, New Brunswick, NJ 08901
------------------------------------------------------------
Item 2(a) Name of Persons Filing:
Citicorp; Citibank, N.A.
------------------------------------------------------------
Item 2(b) Address of Principal Business Offices or, if none, Residence:
399 Park Avenue, New York, New York 10043
(Citicorp and Citibank, N.A.)
------------------------------------------------------------
Item 2(c) Citizenship:
Delaware (Citicorp); New York (Citibank, N.A.)
------------------------------------------------------------
Item 2(d) Title of Class of Securities:
Common Stock, no par value per share
------------------------------------------------------------
Item 2(e) CUSIP Number:
458903101
------------------------------------------------------------
Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b),
check whether the person filing is a:
(a) [ ] Broker or Dealer registered under Section 15 of the Act
(b) [x] Bank as defined in section 3(a)(6) of the Act
(c) [ ] Insurance Company as defined in section 3(a)(19) of the Act
(d) [ ] Investment Company registered under section 8 of the
Investment Company Act
(e) [ ] Investment Adviser registered under section 203 of the
Investment Advisers Act of 1940
Page 4 of 9
<PAGE>
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to the
provisions of the Employee Retirement Income Security Act
of 1974 or Endowment Fund; see ss. 240.13d-1(b)(1)(ii)(F)
(g) [ ] Parent Holding Company, in accordance with
ss. 240.13d-1(b)(ii)(G) (Note: See Item 7)
(h) [ ] Group, in accordance with ss. 240.13d-1(b)(1)(ii)(H)
Item 4 Ownership
If the percent of the class owned, as of December 31 of the
year covered by the statement, or as of the last day of any month described in
Rule 13d-1(b)(2), if applicable, exceeds five percent, provide the following
information as of that date and identify those shares which there is a right to
acquire.
(a) Amount Beneficially Owned:
Citicorp: 1,710,834
------------------------------------------------------------
Citibank, N.A.: 1,710,834
------------------------------------------------------------
(b) Percent of Class:
Citicorp: 4.0%
------------------------------------------------------------
Citibank, N.A.: 4.0%
------------------------------------------------------------
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote -0-
------------
(ii) shared power to vote or to direct the vote
Citicorp: 1,710,834
-----------------------------------------------------
Citibank, N.A.: 1,710,834
-----------------------------------------------------
(iii) sole power to dispose or to direct the
disposition of -0-
--------------------------------------
(iv) shared power to dispose or to direct the
disposition of
Citicorp: 1,710,834
-----------------------------------------------------
Citibank, N.A.: 1,710,834
-----------------------------------------------------
Item 5 Ownership of Five Percent or Less of a Class
Page 5 of 9
<PAGE>
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following [X].
Item 6 Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7 Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company
Not Applicable.
Item 8 Identification and Classification of Members of the Group
Not Applicable.
Item 9 Notice of Dissolution of Group
Not Applicable.
Item 10 Certification
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in the ordinary
course of business and were not acquired for the purpose of and do not have the
effect of changing or influencing the control of the issuer of such securities
and were not acquired in connection with or as a participant in any transaction
having such purposes or effect.
Index of Materials Filed as Exhibits
Exhibit Description
------- -----------
A Joint Filing Agreement
Page 6 of 9
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February 5, 1997
CITICORP
By: /s/ John P. Reilly
------------------------------------------
Name: John P. Reilly
Title: Vice President
Page 7 of 9
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February 5, 1997
CITIBANK, N.A.
By: /s/ William Demick
-----------------------------------------
Name: William Demick
Title: Vice President
Page 8 of 9
<PAGE>
EXHIBIT A
JOINT FILING AGREEMENT
BETWEEN
CITICORP AND CITIBANK, N.A.
The undersigned hereby agree that Amendment No. 2 to Schedule
13G with respect to the common stock, no par value per share, of Interferon
Sciences, Inc., dated February 5, 1997 (the "Amendment No. 2 to Schedule 13G"),
is (including any Schedule 13D with respect to such stock) filed on behalf of
each of us pursuant to and in accordance with the provisions of Rule 13d-1(f)(1)
under the Securities Exchange Act of 1934, as amended. Each of the undersigned
agrees to be responsible for the timely filing of the Amendment No. 2 to
Schedule 13G (including any Schedule 13D with respect to such stock), and for
the completeness and accuracy of the information concerning itself contained
therein.
Dated: February 5, 1997
CITICORP
By: /s/ John P. Reilly
----------------------------------------
Name: John P. Reilly
Title: Vice President
CITIBANK, N.A.
By: /s/ William Demick
----------------------------------------
Name: William Demick
Title: Vice President
Page 9 of 9
